On September 11, 2026 GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE natural killer (NK) cell engager platform, reported it will host a live company presentation on the development of the TriKE platform for cancer treatment, September 11, 2026, at 2:00 p.m. Eastern Time.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, and Dr. Jeffrey Miller, MD1, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers and solid tumors, insights from increasing dose levels, the platform’s competitive positioning, and key milestones ahead.
Webinar Information:
Title: The TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy
Date: Friday, September 11, 2026
Time: 2:00 p.m. Eastern Time
Webcast: Please click here to register.
A replay of the webcast will be made available at gtbiopharma.com following the event.
(Press release, GT Biopharma, SEP 11, 2026, View Source [SID1234670752])